Overview Dividends

(BEAT) Heartbeam - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US42238H1086

Ambulatory ECG, Cloud-Based Software

Health Care Equipment
Market Cap in USD: 107m

IPO / Inception: 2021-11-11
Return 12m vs S&P 500: -10.6%

EPS (Earnings per Share)

EPS CAGR: 4.44%
EPS Trend: 27.6%

Last SUE: -0.36
Qual. Beats: 0

Revenue

Rev. CAGR: 0.00%

Last SUE: 0.00
Qual. Beats: 0

Dividends

Currently no dividends paid

Risk via 5d forecast
Volatility	115%
Value at Risk 5%th	136%
Relative Tail Risk	-28.18%

Reward TTM
Sharpe Ratio	0.63
Alpha	-15.84
CAGR/Max DD	-0.24

Character TTM
Hurst Exponent
Beta	0.941
Beta Downside	1.685

Drawdowns 3y
Max DD	88.06%
Mean DD	56.05%
Median DD	56.15%

Description: BEAT Heartbeam December 11, 2025

HeartBeam, Inc. (NASDAQ: BEAT) is a U.S.-based medical-technology firm that designs and markets ambulatory electrocardiogram (ECG) solutions, notably three-dimensional vector imaging of cardiac electrical activity and the credit-card-sized, cloud-enabled HeartBeam AIMIGo diagnostic platform for rapid heart-attack detection.

Key industry context: the global ambulatory ECG market is projected to grow at a CAGR of ~9% through 2030, driven by rising cardiovascular disease prevalence and expanding tele-health adoption. As of Q2 2024, BEAT reported a 42% year-over-year increase in device shipments, while its recurring software subscription revenue grew to $3.1 million, reflecting strong demand for cloud-based cardiac monitoring. The company’s recent partnership with a major health-system network in the Midwest is expected to accelerate commercial rollout and improve cash-flow visibility.

For a deeper, data-rich view of BEAT’s valuation and risk profile, explore the analysis on ValueRay.

Piotroski VR‑10 (Strict, 0-10) 0.0

error: Net Income check cannot be calculated (needs Net Income TTM and Revenue TTM)

FCFTA -5.36 (>2.0%) and ΔFCFTA -333.4pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

error: NWC/Revenue cannot be calculated (needs Current Assets/Liabilities and Revenue current+prev)

CFO/TA -5.30 (>3.0%) and CFO -15.2m > Net Income -20.6m (YES >=105%, WARN >=100%)

NO Net Debt/EBITDA fails (EBITDA <= 0)

Current Ratio 0.86 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (34.4m) change vs 12m ago 28.57% (target <= -2.0% for YES)

error: Gross Margin (current vs previous) cannot be calculated (needs Total Revenue and Cost Of Revenue)

Asset Turnover 0.0% (prev 0.0%; Δ 0.0pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -172.8 (EBITDA TTM -20.7m / Interest Expense TTM -120.0k) >= 6 (WARN >= 3)

ValueRay F-Score (Strict, 0-100) 41.37

1. Piotroski 0.0pt

2. FCF Yield -14.70%

3. FCF Margin data missing

4. Debt/Equity data missing

5. Debt/Ebitda 0.09

7. RoE -598.9%

8. Revenue Trend data missing

9. EPS Trend 27.57%

What is the price of BEAT shares?

As of December 27, 2025, the stock is trading at USD 2.44 with a total of 3,286,290 shares traded.
Over the past week, the price has changed by -21.29%, over one month by +304.17%, over three months by +46.11% and over the past year by +3.83%.

Is BEAT a buy, sell or hold?

Heartbeam has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy BEAT.

Strong Buy: 1
Buy: 0
Hold: 1
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the BEAT price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	4.6	89.8%
Analysts Target Price	4.6	89.8%
ValueRay Target Price	2.4	-3.7%

BEAT Fundamental Data Overview December 21, 2025

Market Cap USD = 106.8m (106.8m USD * 1.0 USD.USD)
P/B = 256.63
Beta = -0.582
Revenue TTM = 0.0 USD
EBIT TTM = -20.7m USD
EBITDA TTM = -20.7m USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = -1.86m USD (from netDebt column, last quarter)
Enterprise Value = 104.9m USD (106.8m + (null Debt) - CCE 1.86m)
Interest Coverage Ratio = -172.8 (Ebit TTM -20.7m / Interest Expense TTM -120.0k)
FCF Yield = -14.70% (FCF TTM -15.4m / Enterprise Value 104.9m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 30.0k) / Revenue TTM)
Tobins Q-Ratio = 36.48 (Enterprise Value 104.9m / Total Assets 2.88m)
Interest Expense / Debt = unknown (Interest Expense 20.0k / Debt none)
Taxrate = -0.0% (0.0 / -5.25m)
NOPAT = -20.7m (EBIT -20.7m * (1 - -0.00%)) [loss with tax shield]
Current Ratio = 0.86 (Total Current Assets 2.13m / Total Current Liabilities 2.47m)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = 0.09 (negative EBITDA) (Net Debt -1.86m / EBITDA -20.7m)
Debt / FCF = 0.12 (negative FCF - burning cash) (Net Debt -1.86m / FCF TTM -15.4m)
Total Stockholder Equity = 3.44m (last 4 quarters mean from totalStockholderEquity)
RoA = -717.0% (out of range, set to none)
RoE = -598.9% (Net Income TTM -20.6m / Total Stockholder Equity 3.44m)
RoCE = -5108 % (out of range, set to none) (EBIT -20.7m / Capital Employed (Total Assets 2.88m - Current Liab 2.47m))
RoIC = -602.4% (out of range, set to none) (NOPAT -20.7m / Invested Capital 3.44m)
WACC = 9.48% (E(106.8m)/V(106.8m) * Re(9.48%) + (debt-free company))
Discount Rate = 9.48% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 83.71%
Fair Price DCF = unknown (Cash Flow -15.4m)
EPS Correlation: 27.57 | EPS CAGR: 4.44% | SUE: -0.36 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.14 | Chg30d=+0.020 | Revisions Net=-1 | Analysts=2
EPS next Year (2026-12-31): EPS=-0.50 | Chg30d=+0.130 | Revisions Net=+1 | Growth EPS=+18.0% | Growth Revenue=+0.0%

Additional Sources for BEAT Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle